Skip to main content
Triangle logo TriangleGet started

P-Sam (NCT07162480)

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I): a one-minute explainerNCT071624801 min

P-Sam trial for Adenoid Cystic Carcinoma (NCT07162480). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced, recurrent or metastatic adenoid cystic carcinoma meeting aggressive subtype-one criteria: an activating NOTCH mutation, low TP63 expression, or qualifying solid histology and clinical course. Prior treatment limits apply.

The idea: give puxitatug samrotecan infusions every three weeks. Its antibody targets B7-H4 and carries a toxin that disrupts DNA repair. Researchers measure responses and safety. Prior B7-H4-targeted antibody-drug conjugates or topoisomerase-one inhibitors exclude participation.

This phase 2 study plans 28 patients. Renata Ferrarotto leads MD Anderson's recruiting Houston site. This is a single-group study.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.